Related Experiment Video
Updated: Feb 23, 2026
07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
2.9K
Assessing Genetic Expression Profiles in Melanoma Prognosis
Aaron S Farberg1, Alex M Glazer2, Richard R Winkelmann3
1Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Floor 5, New York, NY 10029, USA.
Dermatologic Clinics
|September 10, 2017
Summary
The 31-genetic expression profile (31-GEP) test aids melanoma management by classifying tumors as low or high risk for metastasis. This genomic test improves clinical decision-making and patient care by providing crucial risk stratification data.
Area of Science:
- Oncology
- Genomics
- Dermatology
Background:
- Cutaneous malignant melanoma poses significant management challenges.
- Accurate risk stratification is crucial for effective melanoma patient care.
- Existing methods may not fully capture individual tumor metastatic potential.
Purpose of the Study:
- To evaluate the clinical utility and impact of the 31-genetic expression profile (31-GEP) test.
- To assess the test's ability to classify melanoma lesions by metastatic risk.
- To determine if the 31-GEP test influences clinical management and patient care.
Main Methods:
- Development of the 31-GEP test utilizing expression levels of 28 discriminating and 3 control genes.
- Classification of primary tumors into "low risk" (class 1) or "high risk" (class 2) for metastasis.
- Evaluation of studies assessing the clinical impact and utility of the 31-GEP test.
Main Results:
- The 31-GEP test successfully classifies melanoma lesions based on metastatic risk.
- Studies demonstrated that the 31-GEP test positively influenced clinical management.
- Clinicians utilized the test results to modify treatment recommendations in a risk-appropriate manner.
Conclusions:
- The 31-GEP test is a valuable diagnostic tool for managing cutaneous malignant melanoma.
- Incorporation of 31-GEP test results enhances risk-appropriate clinical decision-making.
- The test contributes to improved patient care by providing precise prognostic information.
